Tradename | Company | Number | Date | Products |
---|---|---|---|---|
RIMACTANE | Oxford Pharmaceuticals | N-050429 RX | 1982-01-01 | 1 products |
RIFADIN | Sanofi | N-050627 RX | 1989-05-25 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
rifadin | 2007-07-16 | |
rifadin iv | New Drug Application | 2024-10-18 |
rifadin iv novaplus | New Drug Application | 2024-10-28 |
rifadin rifadin iv | New Drug Application | 2021-12-01 |
rifadin rifadin iv novaplus | New Drug Application | 2017-05-04 |
rifampin | ANDA | 2024-11-15 |
Drug common name | Rifampin |
INN | rifampicin |
Description | Rifampicin, also known as rifampin, is an ansamycin antibiotic used to treat several types of bacterial infections, including tuberculosis (TB), Mycobacterium avium complex, leprosy, and Legionnaires' disease. It is almost always used together with other antibiotics with two notable exceptions: when given as a "preferred treatment that is strongly recommended" for latent TB infection; and when used as post-exposure prophylaxis to prevent Haemophilus influenzae type b and meningococcal disease in people who have been exposed to those bacteria. Before treating a person for a long period of time, measurements of liver enzymes and blood counts are recommended. Rifampicin may be given either by mouth or intravenously.
|
Classification | Small molecule |
Drug class | tricyclic compounds; antibiotics (rifamycin derivatives) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C |
PDB | — |
CAS-ID | 13292-46-1 |
RxCUI | — |
ChEMBL ID | CHEMBL374478 |
ChEBI ID | 28077 |
PubChem CID | 5381226 |
DrugBank | DB01045 |
UNII ID | VJT6J7R4TR (ChemIDplus, GSRS) |